OR WAIT null SECS
October 12, 2022
CRB’s Horizons: Life Sciences report covers challenges facing manufacturers and how to keep pace with rapid innovation.
Agilent Technologies opened a Dissolution Center of Excellence in Craven Arms, United Kingdom, on Oct. 12, 2022.
October 10, 2022
Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.
Amphista Therapeutics and Domainex will work together to develop treatments focusing on targeted protein degradation.
OGT has launched the SureSeq Myeloid Plus panel and OGT Universal NGS Complete Workflow.
October 02, 2022
Pharmaceutical Technology Europe pays tribute to the role Her Majesty Queen Elizabeth II had in promoting innovation within life sciences.
September 27, 2022
EC has approved Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss.
September 20, 2022
Otsuka announced that the EC has approved Lupkynis as the first oral treatment for active lupus nephritis.
September 16, 2022
EMA has recommended approval of Enjaymo for the treatment of hemolytic anemia in adult patients with cold agglutinin disease.
September 14, 2022
MilliporeSigma’s €130 million (USD$132 million) investment is designed to increase manufacturing capacity of single-use assemblies.